Link between hormone therapy and dementia risk proposed
Men undergoing hormone therapy to treat prostate cancer may be at a higher risk of developing dementia, according to research due to be presented at the American Urological Association annual meeting.Medical Xpress
TUESDAY, July 9, 2019 -- Among elderly patients with prostate cancer, androgen deprivation therapy (ADT) exposure is associated with subsequent diagnosis of Alzheimer disease or dementia, according to a study published online July 3 in JAMA Network...
In total, 13% of men who had received the therapy went on to develop Alzheimer's disease over eight years of follow-up, compared to 9% who hadn't gotten the treatment, the study found.
(University of Pennsylvania School of Medicine) A Penn study of more than 150,000 men with prostate cancer shows androgen deprivation therapy was associated with a higher likelihood of developing dementia when compared to patients who were not exposed to the treatment.
In this study, we identify a link between members of the genus Veillonella and exercise performance. We observed an increase in Veillonella relative abundance in marathon runners postmarathon and isolated a strain of Veillonella atypica from stool samples. Inoculation of this strain into mice significantly increased exhaustive treadmill run time. Veillonella utilize lactate as their sole carbon source, which prompted us to perform a shotgun metagenomic analysis in a cohort of elite athletes, finding that every gene in a major pathway metabolizing lactate to propionate is at higher relative abundance postexercise. Us...
Alzheimer's disease may be a risk for older prostate cancer patients given hormone-blocking treatment
Prostate cancer patients who received hormone-lowering therapy were at higher risk of developing dementia and Alzheimer's disease later on than men who didn't get this treatment, a large U.S. study finds.
Androgen deprivation therapy for prostate cancer is associated with an increased risk of Alzheimer ’s disease and other forms of dementia.
(JAMA Network) Data for 154,089 older men diagnosed with prostate cancer were used to analyze the association between androgen deprivation therapy, a hormone-suppressing therapy used to treat prostate cancer, and subsequent diagnosis of Alzheimer disease or dementia. Of the men, 62,330 (average age 76) received androgen deprivation therapy within two years of being diagnosed with prostate cancer and 91,759 men (average age 74) didn't have such treatment.
ConclusionThis nationwide population ‐based study revealed that ADT was not associated with cerebral infarction after adjusting for potential confounders.
Conclusions: Automated deep learning-based measurements of 18F-choline uptake in the prostate gland were significantly associated with prostate cancer specific survival in patients with hormone-naive prostate cancer. This type of deep learning-based methods could be applied to other prostate cancer PET tracers as well, for example PSMA. C-index and Univariate Cox proportional hazards regression model.Variable ClinicalC-index95% CIHazard ratio95% CIp-valAge0.610.46 - 0.760.970.88 - 1.060.50PSA0.650.50 - 0.791.021.00 - 1.050.034Gleason0.690.47 - 0.921.700.87 - 3.330.12T stage0.740.51 - 0.972.100.79 â" 5.650.14PET/...